Monitor shareholder vote and regulatory approvals (UK High Court sanction) for closing in Q1 2027. The 130% premium to pre-announcement price suggests limited upside from current levels but high certainty of deal completion given board recommendation and competitive process. Watch for any competing bids or regulatory delays.
Price Chart
Executive Summary
Silence Therapeutics announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for $20.00 per ADS in cash, representing a 130% premium to the closing price on October 16, 2026. The all-cash transaction has an enterprise value of $1.1 billion and equity value of approximately $1.3 billion, with closing expected in Q1 2027. This DEFA14A filing contains preliminary solicitation materials (employee letters, FAQ, stakeholder communications) supporting the merger vote.
Key Financial Metrics
Key Facts
- Merck KGaA, Darmstadt, Germany to acquire Silence Therapeutics for $20.00 per ADS in cash
- Enterprise value of $1.1 billion and equity value of approximately $1.3 billion
- 130% premium to the closing price of $8.70 on October 16, 2026
- 82% premium to the 30-day VWAP of $10.99
- Transaction expected to close in Q1 2027
- All-cash consideration of $6.6667 per ordinary share (each ADS = 3 ordinary shares)
- Transaction follows potentially best-in-class Phase 2 polycythemia vera data for Divesiran
- Transaction agreement dated October 19, 2026
- Scheme of arrangement under Part 26 of UK Companies Act 2006
- Board and management conducted a competitive sale process
Financial Impact
All-cash acquisition at $20.00 per ADS, $1.1B enterprise value, ~$1.3B equity value
Risk Factors
- Shareholder approval and regulatory approvals required
- Risk of termination of transaction agreement
- Potential litigation and delay
- Competing acquisition proposals
- Integration and execution risk
- Market volatility and price effects
Investment Themes
Documents Analyzed
This report is based on 13 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-425238 |
| Document: d189864ddefa14a.htm | 0001193125-26-425238 |
| Document: d189864dex991.htm | 0001193125-26-425238 |
| Document: d189864dex997.htm | 0001193125-26-425238 |
| Document: d189864dex993.htm | 0001193125-26-425238 |
| Document: d189864dex994.htm | 0001193125-26-425238 |
| Document: d189864dex996.htm | 0001193125-26-425238 |
| Document: d189864dex995.htm | 0001193125-26-425238 |
| Document: d189864dex998.htm | 0001193125-26-425238 |
| Document: d189864dex999.htm | 0001193125-26-425238 |
| Document: 0001193125-26-425238-index-headers.html | 0001193125-26-425238 |
| Document: 0001193125-26-425238-index.html | 0001193125-26-425238 |
| Document: 0001193125-26-425238.txt | 0001193125-26-425238 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 9d ago | DEFA14A | $19.61 $19.78 | ▲ +0.87% | ▲ +0.79% | $19.78 (+0.87%) |
Oct 19, 2026 9d ago | DEFA14A | $19.58 $19.78 | ▲ +1.02% | ▲ +1.17% | $19.78 (+1.02%) |
Oct 19, 2026 9d ago | 8-K | $19.58 $19.78 | ▲ +1.02% | ▲ +1.17% | $19.78 (+1.02%) |
Oct 13, 2026 15d ago | SC 13G/A | $8.98 $19.67 | ▲ +119.04% | ▲ +118.59% | $19.78 (+120.27%) |
Oct 13, 2026 15d ago | SC 13G | $8.98 $19.67 | ▲ +119.04% | ▲ +118.59% | $19.78 (+120.27%) |
Aug 10, 2026 11w ago | 424B5 | $14.72 $14.10 | ▲ +4.21% | ▲ +3.81% | $19.78 (−34.38%) |
Aug 10, 2026 11w ago | 8-K | $15.43 $14.35 | ▼ −7.00% | ▼ −6.95% | $19.78 (+28.19%) |
Aug 10, 2026 11w ago | 8-K | $15.43 $14.35 | ▼ −7.00% | ▼ −6.95% | $19.78 (+28.19%) |
Jun 23, 2026 18w ago | 8-K | $9.16 $10.50 | ▲ +14.63% | ▲ +12.92% | $19.78 (+115.94%) |
Mar 5, 2026 33w ago | 8-K | $5.50 $6.97 | ▲ +26.73% | ▲ +28.96% | $19.78 (+259.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers